Payment overview · 2025
General Payments
$474.46
40 reported records · 6 companies
Healthcare provider profile · identity verified
Robert Daniel Soliz, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MISSION, TX · NPI 1619434792
Verified facts
What the public records show
CMS Open Payments records show Robert Daniel Soliz, FNP-C received $474.46 in general payments during 2025 across 40 reported records.
GlaxoSmithKline, LLC. accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Linzess, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $179.78 | 37.9% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $151.73 | 32.0% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.08 | 13.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.15 | 7.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $26.78 | 5.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.94 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $474.46 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $150.54 | 17 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $132.21 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $73.83 | 7 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $63.54 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $62.08 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.15 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.24 | 3 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $26.78 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $26.78 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 180 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 251 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
180 | 91 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 35 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
251 | 62 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 478 | 290 |
| Meloxicam | Meloxicam | 302 | 200 |
| Azithromycin | Azithromycin | 276 | 220 |
| Losartan Potassium | Losartan Potassium | 258 | 126 |
| Montelukast Sodium | Montelukast Sodium | 251 | 103 |
| Ozempic | Semaglutide | 251 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 243 | 122 |
| Glipizide | Glipizide | 239 | 130 |
| Metformin Hcl | Metformin Hcl | 238 | 146 |
| Baclofen | Baclofen | 231 | 145 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 230 | 132 |
| Famotidine | Famotidine | 227 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 125 |
| Gabapentin | Gabapentin | 225 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 214 | 113 |
| Fluticasone Propionate | Fluticasone Propionate | 202 | 110 |
| Meclizine Hcl | Meclizine Hcl | 190 | 88 |
| Torsemide | Torsemide | 187 | 83 |
| Tramadol Hcl | Tramadol Hcl | 186 | 61 |
| Ammonium Lactate | Ammonium Lactate | 183 | 70 |
| Linzess | Linaclotide | 180 | 91 |
| Clonazepam | Clonazepam | 176 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 105 |
| Memantine Hcl | Memantine Hcl | 166 | 70 |
| Pregabalin | Pregabalin | 164 | 69 |
| Celecoxib | Celecoxib | 163 | 92 |
| Diclofenac Sodium | Diclofenac Sodium | 159 | 73 |
| Omeprazole | Omeprazole | 138 | 72 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 132 | 97 |
| Buspirone Hcl | Buspirone Hcl | 124 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 66 |
| Trazodone Hcl | Trazodone Hcl | 115 | 50 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 112 | 42 |
| Myrbetriq | Mirabegron | 112 | 44 |
| Telmisartan | Telmisartan | 111 | 62 |
| Finasteride | Finasteride | 106 | 64 |
| Lisinopril | Lisinopril | 102 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 47 |
| Cephalexin | Cephalexin | 99 | 78 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 93 | 60 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 85 | 56 |
| Dicyclomine Hcl | Dicyclomine Hcl | 80 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 46 |
| Potassium Chloride | Potassium Chloride | 75 | 37 |
| Clotrimazole | Clotrimazole | 72 | 49 |
| Furosemide | Furosemide | 70 | 27 |
| Tradjenta | Linagliptin | 70 | 32 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 67 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 35 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 63 | 36 |
| Jardiance | Empagliflozin | 62 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 32 |
| Metoclopramide Hcl | Metoclopramide Hcl | 55 | 34 |
| Mounjaro | Tirzepatide | 53 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 31 |
| Januvia | Sitagliptin Phosphate | 52 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 46 |
| Tresiba Flextouch U-200 | Insulin Degludec | 49 | 22 |
| Ciclopirox | Ciclopirox | 48 | 19 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 45 | 22 |
| Mirtazapine | Mirtazapine | 45 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 45 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 40 |
| Alendronate Sodium | Alendronate Sodium | 43 | 24 |
| Allopurinol | Allopurinol | 42 | 17 |
| Sucralfate | Sucralfate | 40 | 20 |
| Constulose | Lactulose | 39 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 14 |
| Carvedilol | Carvedilol | 38 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 37 | 34 |
| Ofloxacin | Ofloxacin | 37 | 31 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 35 | 20 |
| Trulicity | Dulaglutide | 35 | 12 |
| Lidocaine | Lidocaine | 33 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | 12 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 32 | 15 |
| Trulance | Plecanatide | 32 | 15 |
| Vascepa | Icosapent Ethyl | 32 | 19 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 31 | 28 |
| Mupirocin | Mupirocin | 30 | 27 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 29 | 20 |
| Metronidazole | Metronidazole | 29 | 25 |
| Rybelsus | Semaglutide | 27 | 13 |
| Simvastatin | Simvastatin | 27 | 14 |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | 11 |
| Belsomra | Suvorexant | 25 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 21 |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 21 |
| Scopolamine | Scopolamine | 24 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | 12 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | 11 |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 20 | 11 |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Lactulose | Lactulose | 19 | 17 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Prolia | Denosumab | 17 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $474.46 · 40 records | GlaxoSmithKline, LLC. | AREXVY, BREZTRI, CREON, Cologuard Collection Kit, ENTRESTO, LEQVIO, LINZESS, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error